HLA
DNLI icon

Hamilton Lane Advisors’s Denali Therapeutics DNLI Stock Holding History

Hamilton Lane Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,657
Closed -$596K – 19
2024
Q2 		$596K Buy
+25,657
New +$493K 0.48% 15
2023
Q3 		– Sell
-52,129
Closed -$1.54M – 35
2023
Q2 		$1.54M Buy
+52,129
New +$1.47M 0.68% 27
2021
Q4 		– Sell
-396,944
Closed -$20M – 91
2021
Q3 		$20M Buy
+396,944
New +$22.4M 3.36% 6
2021
Q2 		– Sell
-97,370
Closed -$5.56M – 82
2021
Q1 		$5.56M Buy
+97,370
New +$6.52M 1.81% 12
2019
Q4 		– Sell
-30,948
Closed -$474K – 49
2019
Q3 		$474K Buy
+30,948
New +$591K 0.2% 39

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Hamilton Lane Advisors's DNLI Position: Q3 2024 in Review

Hamilton Lane Advisors sold out of Denali Therapeutics (DNLI) in Q3 2024, closing a stake of 25,657 shares — an estimated $596K sold.

Hamilton Lane Advisors first reported a position in DNLI in Q3 2019 and held it in 5 quarters. The position peaked at $20M in Q3 2021. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2024.

  • Hamilton Lane Advisors reported no remaining Denali Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Hamilton Lane Advisors sold 25,657 Denali Therapeutics shares in Q3 2024, an estimated $596K.
  • Hamilton Lane Advisors first reported a position in Denali Therapeutics in Q3 2019 and held it in 5 quarters.
  • Hamilton Lane Advisors's Denali Therapeutics position peaked at $20M in Q3 2021.
  • 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2024.

Based on Hamilton Lane Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.